Retatrutide: Α triple incretin receptor agonist showing promise in obesity treatment

The increasing prevalence of obesity poses a significant challenge for healthcare providers worldwide. However, the recent advancements in the development of drugs for obesity treatment offer hope for effectively addressing this global health concern. The success of semaglutide and tirzepatide, GLP-1 receptor agonists, in targeting the neuroendocrine mechanisms responsible for obesity represents a significant milestone. The introduction of retatrutide, a novel drug for obesity treatment, is also a promising development for the field. The ongoing phase 2a clinical trials provide an opportunity to evaluate the safety and efficacy of this new therapeutic option. Aim of this systematic review is to present comprehensive information on the anti-obesity action of this GlP-1 receptor agonist at hand. Detailed research was conducted via the PubMed database using the keywords: "retatrutide" and "obesity or weight loss". No further filters were applied. Clinical trials have shown substantial weight loss with the use of Retatrutide, in patients with obesity. Further research is necessary to ascertain the safety of this GLP-1 receptor agonist in question and to conduct comparative analyses with other similar agonists. These clinical trials will provide valuable insights into the efficacy and performance of the drug, which will be useful in determining its potential for use in medical treatment for obesity.